ICW Investment Advisors LLC Grows Stock Position in Novo Nordisk A/S (NYSE:NVO)

ICW Investment Advisors LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,142 shares of the company’s stock after purchasing an additional 472 shares during the quarter. Novo Nordisk A/S makes up approximately 1.5% of ICW Investment Advisors LLC’s holdings, making the stock its 15th biggest position. ICW Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,539,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in NVO. Victory Capital Management Inc. increased its holdings in Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after acquiring an additional 23,223 shares in the last quarter. Norman Fields Gottscho Capital Management LLC increased its holdings in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC increased its holdings in Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after acquiring an additional 30,420 shares in the last quarter. Versant Capital Management Inc purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $86,000. Finally, Talbot Financial LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $4,066,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Down 2.4 %

NYSE NVO opened at $76.88 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market capitalization of $344.98 billion, a P/E ratio of 23.37, a P/E/G ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a one year low of $73.80 and a one year high of $148.15. The stock has a 50 day moving average price of $83.34 and a 200-day moving average price of $100.74.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.